Byrd, Brook K.
Wells, Wendy A.
Strawbridge, Rendall R.
Barth, Connor W.
Samkoe, Kimberley S.
Gibbs, Summer L.
Davis, Scott C.
Funding for this research was provided by:
National Institutes of Health (R01CA188491)
Article History
Received: 1 July 2022
Revised: 22 August 2022
Accepted: 6 September 2022
First Online: 23 June 2023
Declarations
:
: Dr. Samkoe, Dr. Wells, and Mr. Strawbridge have nothing to disclose. Dr. Barth reports grants from National Institute of Health, during the conduct of the study, and personal fees and non-financial support from Inherent Targeting, outside the submitted work. Mrs. Byrd reports personal fees from CairnSurgical LLC., outside the submitted work. Dr. Davis reports grants from NIH, during the conduct of the study; personal fees from GV LLP (formerly Google Ventures), other from DoseOptics, LLC, outside the submitted work; in addition, Dr. Davis has a patent Surgical navigation with stereovision and associated methods issued; a patent Method And Apparatus For Depth-Resolved Fluorescence, Chromophore, and Oximetry Imaging For Lesion Identification During Surgery issued; and a patent Methods for Quantitative and Enhanced-Contrast Molecular Medical Imaging using Cross-modality Correction for Differing Tracer Kinetics pending. Dr. Gibbs reports grants from National Cancer Institute, during the conduct of the study; and Dr. Summer Gibbs is a co-founder and shareholder of Inherent Targeting. The work presented herein is unrelated to the development work at Inherent Targeting, but is in the same fluorescence guided surgery research space.